Heat made AZ's FluMist ineffective against swine flu; Diamyd begins diabetes jab trial;

> FluMist maker AstraZeneca ($AZN) blames heat for its vaccine's ineffectiveness against swine flu. Report

> Diamyd Medical has dosed the first patient in its Type 1 diabetes vaccine study. Release

> ACIP has recommended Merck's ($MRK) Gardasil 9 for females ages 9 to 26 and males ages 9 to 21. Release

> In a Phase I study, Themis Bioscience's Chikungunya vaccine candidate raised concentrations of neutralizing antibodies in three dose cohorts after one immunization. Release

> Targovax has appointed Øystein Soug as its new CFO. Release

And Finally... The CDC says flu vaccines were only 18% effective this season. Report (reg. req.)

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.